Angiogenèse : l'exemple du cancer rénal

25 novembre 2008

Auteurs : A. Méjean, T. Lebret
Référence : Prog Urol, 2008, 18, S309, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Loeb L.A. Mutator phenotype may be required for multistage carcinogenesis Cancer Res 1991 ;  51 (12) : 3075-3079
 
Hahn W.C., Weinberg R.A. Rules for making human tumor cells N Engl J Med 2002 ;  347 (20) : 1593-1603 [cross-ref]
 
Latif F., Tory K., Gnarra J., Yao, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene Science 1993 ;  260 (5112) : 1317-1320
 
Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., Latif F., Liu S., Chen F., Duh F.M., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 1994 ;  7 (1) : 85-90 [cross-ref]
 
Shuin T., Kondo K., Torigoe S., Kishida T., Kubota Y., Hosaka M., Nagashima Y., Kitamura H., Latif F., Zbar B., et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas Cancer Res 1994 ;  54 (11) : 2852-2855
 
Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., Samid D., Duan D.S., Gnarra J.R., Linehan W.M., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma Proc Natl Acad Sci U S A 1994 ;  91 (21) : 9700-9704 [cross-ref]
 
Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 2002 ;  1 (3) : 237-246 [cross-ref]
 
Rini B.I., Rathmell W.K. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma Clin Cancer Res 2007 ;  13 (2 Pt 2) : 741s-746s
 
Patel P.H., Chadalavada R.S., Chaganti R.S., Motzer R.J. Targeting von Hippel-Lindau pathway in renal cell carcinoma Clin Cancer Res 2006 ;  12 (24) : 7215-7220 [cross-ref]
 
Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer J Clin Oncol 2004 ;  22 (24) : 4991-5004 [cross-ref]
 
Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex Proc Natl Acad Sci U S A 2000 ;  97 (19) : 10430-10435 [cross-ref]
 
Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 2005 ;  23 (5) : 1011-1027 [cross-ref]
 
Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors Nat Med 2003 ;  9 (6) : 669-676 [cross-ref]
 
Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., Abraham J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing J Biol Chem 1991 ;  266 (18) : 11947-11954
 
Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 1983 ;  219 (4587) : 983-985
 
Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 2002 ;  20 (21) : 4368-4380 [cross-ref]
 
Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nat Cell Biol 2000 ;  2 (10) : 737-744
 
Brown L.F., Yeo K.T., Berse B., Yeo T.K., Senger D.R., Dvorak H.F., van de Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing J Exp Med 1992 ;  176 (5) : 1375-1379 [cross-ref]
 
Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions Nat Med 2001 ;  7 (5) : 575-583 [cross-ref]
 
Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis Nat Rev Cancer 2005 ;  5 (9) : 735-743 [cross-ref]
 
Achen M.G., Mann G.B., Stacker S.A. Targeting lymphangiogenesis to prevent tumour metastasis Br J Cancer 2006 May 22 ;  94 (10) : 1355-1360 [cross-ref]
 
Ogawa S., Oku A., Sawano A., Yamaguchi S., Yazaki Y., Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain J Biol Chem 1998 ;  273 (47) : 31273-31282 [cross-ref]
 
Soker S. Neuropilin in the midst of cell migration and retraction Int J Biochem Cell Biol 2001 ;  33 (4) : 433-437 [cross-ref]
 
Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor Am J Physiol Cell Physiol 2001 ;  280 (6) : C1375-C1386
 
Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis Recent Prog Horm Res 2000 ;  55 : 15-35
 
Meadows K.N., Bryant P., Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation J Biol Chem 2001 ;  276 (52) : 49289-49298 [cross-ref]
 
Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family Cardiovasc Res 2001 ;  49 (3) : 568-581 [cross-ref]
 
Purhonen S., Palm J., Rossi D., Kaskenpää N., Rajantie I., Ylä-Herttuala S., Alitalo K., Weissman I.L., Salven P. Bone marrowderived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth Proc Natl Acad Sci U S A 2008 ;  105 (18) : 6620-6625 [cross-ref]
 
Kaplan R.N., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Nature 2005 ;  438 (7069) : 820-827 [cross-ref]
 
Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., Kaelin W.G. TSC2 regulates VEGF through mTOR-dependent and independent pathways Cancer Cell 2003 ;  4 (2) : 147-158 [cross-ref]
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.